NCT04023812Completed
Stage III NSCLC RWE in Chinese Patients
Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients With Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)
Source: ClinicalTrials.gov · Last updated 18 Feb 2025
Brief summary (registry, in English)
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 500 (actual)
- First submitted
- 30 May 2019
- Start date
- 16 Jul 2019
- Primary completion date
- 29 Feb 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT04023812
What you commit to
- Study type: Observational
- Participants enrolled: 500
- From 16 Jul 2019 to the primary completion date, 29 Feb 2024
- 17 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.
Other
- Enrolment in studies that prohibit any participation in this observational study.
- Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.
Who the study is looking for
- Male or female aged 18 years or older.
- Provision of informed consent prior to any study specific procedures.
- Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study.Target Oncol · 2026 · PMID 42070217
This page is information, not medical advice. Discuss any trial with your doctor.